Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence

Murray, Nigel P; Reyes, Eduardo; Fuentealba, Cynthia; Orellana, Nelson

doi:10.7314/apjcp.2015.16.15.6615

Cited by 8 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with the higher HER2 expression detection in 53% of mCRPC bone metastases described by Day et al [ 10 ]. Moreover, many of our patients previously received ARSI, which could be correlated with HER2 expression in CTCs in previous studies [ 14 ].…”

Section: Discussionmentioning

confidence: 80%

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

Maillet

Allioli

Péron

et al. 2021

Cancers

View full text Add to dashboard Cite

HER2-dependent signaling may support the development of metastatic castration-resistant prostate cancer (mCRPC) by activating androgen receptor signaling through ligand-independent mechanisms. From 41 mCRPC patients (including 31 treated with Androgen Receptor Signaling Inhibitors [ARSI]), Circulating Tumor Cells (CTCs) were prospectively enriched with AdnaTest platform and analyzed with a multiplexed assay for HER2 and AR-V7 mRNA expression. Then, we evaluated the impact of HER2 expression on PSA-response, Progression Free Survival (PFS) and Overall Survival (OS). HER2 expression was detected in CTCs of 26 patients (63%). Although PSA response was similar regardless of HER2 status, patients with HER2 positive CTCs had shorter PSA-PFS (median: 6.2 months versus 13.0 months, p = 0.034) and radiological-PFS (6.8 months versus 25.6 months, p = 0.022) than patients without HER2 expression. HER2 expression was also associated with a shorter OS (22.7 months versus not reached, p = 0.05). In patients treated with ARSI, multivariate analyses revealed that the prognostic impact of HER2 status on PSA-PFS was independent of AR-V7 expression and of the detection of CTCs by an AdnaTest. We showed for the first time the poor prognostic value of HER2 expression in CTCs from patients with mCRPC. The therapeutic interest of targeting this actionable pathway remains to be explored.

show abstract

Section: Discussionmentioning

confidence: 80%

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

Maillet

Allioli

Péron

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Prostate cancer and bone marrow micrometastasis contained both HER-2 positive and negative cells, that the risk of treatment failure was similar in patients with HER-2 positive and negative micrometastasis. However, after starting ADT there was selection of HER-2 expressing cells, HER-2 negative cells being eradicated and these men had a higher risk of progressing to castrate resistant prostate cancer and a shorter time to treatment failure with ADT [126, 127]. …”

Section: Changing the Soil Selects The Seed—paget Revisitedmentioning

confidence: 99%

Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management

Murray

2018

Biol Res

View full text Add to dashboard Cite

Minimal residual disease is that not detected by conventional imaging studies and clinically the patient remains disease free. However, with time these dormant cells will awaken and disease progression occurs, resulting in clinically and radiological detectable metastatic disease. This review addresses the concept of tumor cell dissemination from the primary tumor, the micrometastatic niche and tumor cell survival and finally the clinical utility of detecting and characterizing these tumor cells in order to guide management decisions in treating patients with prostate cancer.

show abstract

Re-expression of microRNA-4319 inhibits growth of prostate cancer via Her-2 suppression

Lin

Wang

2018

Clin Transl Oncol

View full text Add to dashboard Cite

show abstract

Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence

Cited by 8 publications

References 18 publications

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management

Re-expression of microRNA-4319 inhibits growth of prostate cancer via Her-2 suppression

Contact Info

Product

Resources

About